Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Centanafadine→

Centanafadine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
924012-43-1
Molecular formula
C15H15N
Molecular weight
209.29 g/mol
Drug class
Norepinephrine–dopamine–serotonin reuptake inhibitor (NDSRI)central nervous system stimulant
Mechanism of action
Inhibits the norepinephrine, dopamine and serotonin reuptake transporters. The mechanism by which centanafadine produces clinical benefit in ADHD is not fully established, but its efficacy may be mediated by increased availability of these monoamine neurotransmitters.
Indications / reported uses
  • Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and paediatric patients aged 6 years and older weighing at least 20 kg under the US FDA SIMTRIYO indication (approved 24 July 2026); not recommended in children under 6 years or weighing less than 20 kg

Sources: NLM DailyMed — SIMTRIYO (centanafadine hydrochloride), label updated 31 July 2026 · Federal Register — Centanafadine Schedule III rule, 30 October 2026 · FDA — Centanafadine approval snapshot · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Norepinephrine–dopamine–serotonin reuptake inhibitor (NDSRI); central nervous system stimulant

Mechanism of action

Inhibits the norepinephrine, dopamine and serotonin reuptake transporters. The mechanism by which centanafadine produces clinical benefit in ADHD is not fully established, but its efficacy may be mediated by increased availability of these monoamine neurotransmitters.

General use cases

  • Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and paediatric patients aged 6 years and older weighing at least 20 kg under the US FDA SIMTRIYO indication (approved 24 July 2026); not recommended in children under 6 years or weighing less than 20 kg

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Centanafadine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Centanafadine Permitted Daily Exposure (PDE) report (the Centanafadine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Centanafadine Occupational Exposure Limit (OEL) report (the Centanafadine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.